Hyperuricemia And Gout Are Associated With Cancer Incidence And Mortality: A Meta-Analysis Based On Cohort Studies

The association between hyperuricemia or gout and cancer risk has been investigated in various published studies, but their results are conflicting. We conducted a meta-analysis to investigate whether hyperuricemia or gout was associated with the cancer incidence and mortality. Linear and nonlinear trend analyses were conducted to explore the dose-response association between them. The pooled relative risk (RR) and 95% confidence interval (CI) were used to evaluate cancer risk. A total of 24 articles (33 independent studies) were eligible for inclusion. When compared participants with the highest SUA (hyperuricemia) levels and those with the lowest SUA levels, the pooled RR was 1.08 (95% CI, 1.04-1.12), it was significantly associated among males but not among females (males, RR=1.07; 95% CI, 1.03-1.11; females, RR=1.06; 95% CI, 0.96-1.17). Hyperuricemia increased total cancer mortality (RR=1.15; 95% CI, 1.05-1.26), but a significant association was observed in females rather than in males (females: RR=1.26; 95% CI, 1.09-1.45; males, RR=1.02; 95% CI, 0.80-1.30). Linear relationships of SUA levels with overall cancer incidence (p for nonlinearity=0.238) and overall cancer mortality (p for nonlinearity=0.263) were identified. However, 1 mg/dL increment in SUA levels was weakly significant in overall cancer incidence (RR=1.01; 95% CI, 1.01-1.01) but not associated with overall cancer mortality (RR=1.01; 95% CI, 0.99-1.03). Gout was significantly associated with increased cancer incidence (RR=1.19; 95% CI, 1.12-1.25). In conclusion, Hyperuricemia or gout was associated with higher cancer incidence and mortality. Though a potential linear relationship between them was found, we'd better treat this result with caution.